Key Takeaways
- Azitra (AZTR) shares climbed as high as 87% Friday following the disclosure of a private placement transaction
- The financing secures an initial $10.5 million via preferred stock, with potential for up to $31.4 million total when warrant exercises are included
- The investor group features Stonepine Capital, Nantahala Capital, healthcare industry professionals, and company leadership including the CEO
- Funds will support the development of filaggrin-based proteins and peptides targeting the cosmeceutical industry
- The company faces a NYSE American delisting notice due to insufficient stockholders’ equity and has declined more than 91% over the last year
Shares of Azitra (AZTR) skyrocketed by as much as 87% during Friday’s trading session after the biotechnology firm disclosed specifics of a private placement transaction capable of generating up to $31.4 million in total gross proceeds.
The transaction reached closure on or near Friday, subject to standard closing conditions. This surge came after a 28.82% gain the previous trading day when initial placement details emerged.
The capital raise features a two-tier structure. The company secured an immediate $10.5 million by selling 10,470 shares of Series A convertible non-redeemable preferred stock priced at $1,000 each.
An additional $20.9 million may be realized through the cash exercise of Series B and Series C warrants. Each warrant series grants holders the right to acquire up to 85,101,201 common shares at $0.123 per share.
Each preferred share will automatically convert into approximately 8,129 common shares once stockholder approval is obtained. Series B Warrants carry an expiration date 18 months following that approval. Series C Warrants will expire 30 days after Azitra releases results from an upcoming human cosmetic clinical study.
Trading activity surged dramatically on the announcement. Friday’s session saw more than 166 million AZTR shares traded, a massive increase from the three-month daily average of approximately 170,000.
Intended Use of Capital
Azitra intends to allocate the capital toward advancing proteins and peptides designed for the consumer cosmeceutical sector, with particular emphasis on filaggrin-based technology. The company employs a microbial genetic engineering platform for this development work.
The financing will also cover general corporate operations, research and development initiatives, and working capital requirements.
The investor syndicate includes Stonepine Capital, Nantahala Capital, additional institutional healthcare-focused funds, medical professionals, and company management — including the Chief Executive Officer’s participation.
Financial Context
The stock’s recent performance paints a challenging picture. Before this week’s rally, AZTR traded near $0.14, representing a decline of approximately 94% year-over-year. The company’s market capitalization stood at merely $2.21 million.
Cash consumption remains high, with levered free cash flow registering negative $10.93 million over the trailing twelve months. However, the company maintains a stronger cash position than debt burden, with a current ratio of 2.83.
AZTR has also been notified by NYSE American regarding potential delisting. The exchange cited non-compliance with Section 1003(a)(iii), which mandates minimum stockholders’ equity of $6 million for entities reporting losses from continuing operations across five consecutive fiscal years.
Azitra must address this deficiency to maintain its exchange listing.
From an analyst perspective, Jason McCarthy of Maxim Group provides the only published coverage on AZTR, maintaining a Buy rating alongside a $1 price target.
Despite this week’s surge, AZTR remains down 33.3% year-to-date.
